Originally published by our sister publication Infectious Disease Special Edition
By Landon Gray
Remdesivir (Veklury, Gilead) may reduce risk for hospital readmission by as much as 16% among immunocompromised COVID-19 patients, according to a study presented at the 2023 European Congress of Clinical Microbiology & Infectious Diseases, in Copenhagen, Denmark (abstract O0427).
Previous studies have described the effectiveness of remdesivir against COVID-19, but there are limited data on the